

# Democratic People's Republic of Korea

Population 2017

25 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	16 (11–22)	63 (43–86)
Mortality (HIV+TB only)	0.044 (0.022–0.072)	0.17 (0.09–0.28)
Incidence (includes HIV+TB)	131 (114–149)	513 (446–584)
Incidence (HIV+TB only)	0.17 (0.094–0.28)	0.69 (0.37–1.1)
Incidence (MDR/RR-TB)**	5.2 (2.6–8.8)	20 (10–34)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	6.2 (6–6.4)	43 (40–47)	50 (45–54)
Males	8.4 (8.1–8.6)	73 (66–80)	81 (73–90)
Total	15 (14–15)	116 (101–131)	131 (114–149)

TB case notifications, 2017	
Total cases notified	107 103
Total new and relapse	100 553
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	81%
- % bacteriologically confirmed among pulmonary	50%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	77% (68–88)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.12 (0.08–0.17)

TB/HIV care in new and relapse TB patients, 2017		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			4 100 (2 300–5 800)
Estimated % of TB cases with MDR/RR-TB	2.2% (0.82–4.2)	16% (9.1–25)	
% notified tested for rifampicin resistance		14%	2 116
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 1 515, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1 732, XDR-TB: 19	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2016		
Previously treated cases registered in 2016		
HIV-positive TB cases registered in 2016		
MDR/RR-TB cases started on second-line treatment in 2015	73%	325
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	> 100%

TB financing, 2018	
National TB budget (US\$ millions)	84
Funding source: 7% domestic, 1% international, 92% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically